UBS Group’s MetLife MET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $206M | Sell |
2,440,347
-1,164,821
| -32% | -$93.9M | 0.03% | 647 |
|
|
2026
Q1 | $255M | Buy |
3,605,168
+1,140,426
| +46% | +$85.4M | 0.04% | 500 |
|
|
2025
Q4 | $195M | Buy |
2,464,742
+6,057
| +0.2% | +$479K | 0.03% | 587 |
|
|
2025
Q3 | $203M | Sell |
2,458,685
-453,107
| -16% | -$35.7M | 0.03% | 579 |
|
|
2025
Q2 | $234M | Sell |
2,911,792
-479,616
| -14% | -$37M | 0.04% | 468 |
|
|
2025
Q1 | $272M | Buy |
3,391,408
+1,058,152
| +45% | +$88M | 0.05% | 383 |
|
|
2024
Q4 | $191M | Sell |
2,333,256
-199,341
| -8% | -$16.6M | 0.04% | 539 |
|
|
2024
Q3 | $209M | Buy |
2,532,597
+32,893
| +1% | +$2.46M | 0.05% | 391 |
|
|
2024
Q2 | $175M | Buy |
2,499,704
+449,750
| +22% | +$32.1M | 0.04% | 394 |
|
|
2024
Q1 | $152M | Buy |
2,049,954
+222,711
| +12% | +$15.5M | 0.04% | 458 |
|
|
2023
Q4 | $121M | Buy |
1,827,243
+489,906
| +37% | +$30.7M | 0.04% | 494 |
|
|
2023
Q3 | $84.1M | Buy |
1,337,337
+208,422
| +18% | +$13M | 0.03% | 572 |
|
|
2023
Q2 | $63.8M | Sell |
1,128,915
-635,361
| -36% | -$35.3M | 0.02% | 698 |
|
|
2023
Q1 | $102M | Buy |
1,764,276
+75,902
| +4% | +$5.12M | 0.04% | 451 |
|
|
2022
Q4 | $122M | Buy |
1,688,374
+414,547
| +33% | +$29.7M | 0.05% | 422 |
|
|
2022
Q3 | $77.4M | Sell |
1,273,827
-694,439
| -35% | -$44.4M | 0.03% | 521 |
|
|
2022
Q2 | $124M | Buy |
1,968,266
+137,350
| +8% | +$9.09M | 0.05% | 381 |
|
|
2022
Q1 | $129M | Sell |
1,830,916
-164,238
| -8% | -$11.1M | 0.04% | 434 |
|
|
2021
Q4 | $125M | Sell |
1,995,154
-150,000
| -7% | -$9.41M | 0.04% | 512 |
|
|
2021
Q3 | $132M | Sell |
2,145,154
-310,183
| -13% | -$18.7M | 0.04% | 442 |
|
|
2021
Q2 | $147M | Buy |
2,455,337
+241,642
| +11% | +$15.3M | 0.05% | 393 |
|
|
2021
Q1 | $135M | Buy |
2,213,695
+173,201
| +8% | +$9.56M | 0.04% | 394 |
|
|
2020
Q4 | $95.8M | Sell |
2,040,494
-783,845
| -28% | -$34M | 0.03% | 504 |
|
|
2020
Q3 | $105M | Buy |
2,824,339
+727,970
| +35% | +$27.6M | 0.04% | 384 |
|
|
2020
Q2 | $76.6M | Sell |
2,096,369
-1,412,771
| -40% | -$49.2M | 0.03% | 444 |
|
|
2020
Q1 | $107M | Buy |
3,509,140
+495,006
| +16% | +$21.9M | 0.05% | 327 |
|
|
2019
Q4 | $154M | Sell |
3,014,134
-1,024,465
| -25% | -$49.5M | 0.05% | 320 |
|
|
2019
Q3 | $190M | Buy |
4,038,599
+1,433,848
| +55% | +$68.4M | 0.07% | 253 |
|
|
2019
Q2 | $129M | Sell |
2,604,751
-124,935
| -5% | -$5.87M | 0.05% | 330 |
|
|
2019
Q1 | $116M | Buy |
2,729,686
+395,300
| +17% | +$17.5M | 0.05% | 349 |
|
|
2018
Q4 | $95.8M | Sell |
2,334,386
-408,184
| -15% | -$17.5M | 0.04% | 378 |
|
|
2018
Q3 | $128M | Sell |
2,742,570
-148,839
| -5% | -$6.8M | 0.05% | 340 |
|
|
2018
Q2 | $126M | Sell |
2,891,409
-359,305
| -11% | -$16.8M | 0.05% | 329 |
|
|
2018
Q1 | $149M | Sell |
3,250,714
-610,852
| -16% | -$29.6M | 0.06% | 288 |
|
|
2017
Q4 | $195M | Buy |
3,861,566
+168,992
| +5% | +$8.9M | 0.08% | 253 |
|
|
2017
Q3 | $192M | Sell |
3,692,574
-155,951
| -4% | -$7.59M | 0.09% | 231 |
|
|
2017
Q2 | $188M | Sell |
3,848,525
-183,652
| -5% | -$8.52M | 0.1% | 224 |
|
|
2017
Q1 | $190M | Buy |
4,032,177
+34,185
| +0.9% | +$1.63M | 0.1% | 223 |
|
|
2016
Q4 | $192M | Sell |
3,997,992
-2,072,500
| -34% | -$95.1M | 0.11% | 213 |
|
|
2016
Q3 | $240M | Buy |
6,070,492
+1,157,328
| +24% | +$43.5M | 0.14% | 165 |
|
|
2016
Q2 | $174M | Buy |
4,913,164
+329,695
| +7% | +$12.9M | 0.11% | 200 |
|
|
2016
Q1 | $179M | Sell |
4,583,469
-734,652
| -14% | -$27.5M | 0.12% | 182 |
|
|
2015
Q4 | $229M | Buy |
5,318,121
+1,010,808
| +23% | +$44.4M | 0.15% | 152 |
|
|
2015
Q3 | $181M | Sell |
4,307,313
-947,795
| -18% | -$44.3M | 0.13% | 181 |
|
|
2015
Q2 | $262M | Sell |
5,255,108
-1,241,447
| -19% | -$58.8M | 0.17% | 131 |
|
|
2015
Q1 | $293M | Buy |
6,496,555
+419,334
| +7% | +$18.8M | 0.2% | 114 |
|
|
2014
Q4 | $293M | Buy |
+6,077,221
| New | +$289M | 0.2% | 108 |
|
Other funds holding MET
UBS Group's MET Position: Q2 2026 in Review
UBS Group reduced its MetLife (MET) stake by 32% in Q2 2026, selling an estimated $93.9M and leaving 2,440,347 shares worth $206M. The position accounts for 0.03% of the portfolio, ranked #647.
UBS Group first reported a position in MET in Q4 2014 and has held it in 47 quarters since. The position peaked at $293M in Q4 2014. 1,442 funds tracked by Wall St. Rank hold MET as of Q2 2026.
- UBS Group held 2,440,347 shares of MetLife worth $206M as of Q2 2026.
- UBS Group sold 1,164,821 MetLife shares in Q2 2026, an estimated $93.9M.
- MetLife made up 0.03% of UBS Group's portfolio in Q2 2026, its #647 holding.
- UBS Group first reported a position in MetLife in Q4 2014 and has held it in 47 quarters since.
- UBS Group's MetLife position peaked at $293M in Q4 2014.
- 1,442 funds tracked by Wall St. Rank held MetLife as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.